Overall, it was found that various caregiver-specific variables were adopted as endpoints within ADRD clinical trials. Analysis of methodological rigor revealed that a number of such investigations were embedded within high quality parent studies of drug efficacy. Randomization and intervention details were usually described clearly by study authors. In contrast to traditional nondrug caregiver intervention studies, the reports reviewed here routinely specified the type, severity, and diagnostic criteria of the dementia disorder under study, and except for a small number of the open-label studies, most trials had sufficiently large sample sizes.